Abstract
OBJECTIVE: A large majority of urinary tract infections are caused by coliform organisms. Trimethoprim-sulfamethoxazole (TMP-SMX) resistance among uropathogens is increasing in many areas. The objective of this study was to determine risk factors for TMP-SMX-resistant coliforms in patients with urinary tract infections.
DESIGN: Retrospective case-control study.
SETTING: Emergency department of a tertiary care university hospital.
PATIENTS: We studied 448 emergency department patients aged 14 years or older with a urinary tract infection caused by a coliform organism. Cases consisted of all patients with a culture-documented urinary tract infection caused by a TMP-SMX-resistant coliform, while control patients were those with a TMP-SMX-sensitive organism.
MEASUREMENTS AND MAIN RESULTS: A univariate analysis of clinical variables associated with TMP-SMX resistance was performed. Multiple logistic regression was performed to determine independent predictors of TMP-SMX resistance. Resistance to TMP-SMX was seen in 15% of isolates. Numerous variables were associated with TMP-SMX resistance on the univariate screen. Independent predictors of resistance were diabetes (odds ratio [OR] 3.1; 95% confidence interval [CI] 1.2, 8.4), recent hospitalization (OR 2.5; 95% CI 1.1, 5.7), current use of antibiotics (OR 4.5; 95% CI 2.0, 10.2), and recent use of TMP-SMX (OR 5.1; 95% CI 2.2, 11.5). When those with recent hospitalization were excluded from analysis, independent predictors were current use of any antibiotic (OR 3.5; 95% CI 1.4, 8.4) and recent use of TMP-SMX (OR 5.9; 95% CI 2.4, 14.3).
CONCLUSIONS: Coliforms resistant to TMP-SMX are common in our emergency department. Diabetes, recent hospitalization, and the use of antibiotics, particularly the use of TMP-SMX, are independent risk factors for TMP-SMX resistance, Clinicians should consider these findings when deciding on antimicrobial therapy for patients with urinary tract infections.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Levy SB. Confronting multidrug resistance: a role for each of us. JAMA. 1993;269:1840–2.
Tenover FC, Hughes JM. The challenges of emerging infectious diseases: development and spread of multiply-resistant bacterial pathogens. JAMA. 1996;275:300–4.
Hoffman J, Cetron MS, Farley MM, et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N Engl J Med. 1995;333:481–6.
Stamm WE, Hooton TM. Management of urinary tract infection in adults. N Engl J Med. 1993;329:1328–34.
Marco CA, Parker K. Antimicrobial resistance among organisms causing urinary tract infection. Acad Emerg Med. 1997;4:159–60.
Sanford JP, Gilbert DN, Sande MA. Sanford Guide: Guide to Antimicrobial Therapy-1997. Dallas, Tex: Antimicrobial Therapy, Inc.; 1997.
Huovinen P. Increases in rates of resistance to trimethoprim. Clin Infect Dis. 1997;24 (suppl 1):S63–6.
Murdoch DA, Spillman I, Kabare P. Antibiotic availability and multiresistant coliforms in a rural Ugandan hospital. J Trop Med Hyg. 1995;98:25–8.
Lester SC, del Pilar Pla M, Wang F, et al. The carriage of Escherichia coli resistant to antimicrobial agents by healthy children in Boston, in Caracas, Venezuela, and in Qin Pu, China. N Engl J Med. 1990;323:285–9.
Bonten M, Stobberingh E, Philips J, Houben A. Antibiotic resistance of Escherichia coli in fecal samples of healthy people in two different areas in an industrialized country. Infection. 1992;10:258–62.
Martin JN, Rose DA, Hadley WK. Perdreau-Remington F, Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. Clin Infect Dis. 1996;23:906. Abstract.
Hooton TM, Winter C, Tiu F, Stamm WE. Randomized comparative trial and cost analysis of 3-day antimicrobial regimens for treatment of acute cystitis in women. JAMA. 1995;273:41–5.
Eiband JD, Allen MK, Lerner P. Prediction of resistant urinary tract infections in the geriatric population. Ann Emerg Med. 1991;20:463. Abstract.
Ena J, Amador C, Martinez C, Ortiz de la Tabla V. Risk factors for acquisition of urinary tract infections caused by ciprofloxacin resistant Escherichia coli. J Urol. 1995;153:117–20.
Akram J, Glatt AE. Multiply-drug resistant (MDR) E. coli. Clin Infect Dis. 1997;24:494. Abstract.
Patterson JE, Andriole VT. Bacterial urinary tract infections in diabetes. Infect Dis Clin North Am. 1997;11:735–50.
Jones RN. Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. Am J Med. 1996;100(suppl 6A):3S-12S.
Levin BR, Lipsitch M, Perrot V, et al. The population genetics of antibiotic resistance. Clin Infect Dis. 1997;24(suppl 1):S9–16.
Nicolle LE, Hoepelman AIM, Floor M, Verhoef J, Norgard K. Comparison of three days’ therapy with cefcanel or amoxicillin for the treatment of acute uncomplicated urinary tract infection. Scand J Infect Dis. 1993;25:631–7.
Masterson RG, Bochsler JA. High-dosage co-amoxiclav in a single dose versus 7 days of co-trimoxazole as treatment of uncomplicated lower urinary tract infection in women. J Antimicrob Chemother. 1995;35:129–37.
Nicolle LE, Louie TJ, Dubois J, et al. Treatment of complicated urinary tract infections with lomefloxacin compared with that with trimethoprim-sulfamethoxazole. Antimicrob Agents Chemother. 1994;38:1368–73.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Wright, S.W., Wrenn, K.D. & Haynes, M.L. Trimethoprim-sulfamethoxazole resistance among urinary coliform isolates. J GEN INTERN MED 14, 606–609 (1999). https://doi.org/10.1046/j.1525-1497.1999.10128.x
Issue Date:
DOI: https://doi.org/10.1046/j.1525-1497.1999.10128.x